Inovio Pharmaceuticals, Inc.
INO
$1.64
-$0.04-2.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.30K | 182.30K | 182.30K | 283.10K | 217.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.30K | 182.30K | 182.30K | 283.10K | 217.80K |
| Cost of Revenue | 54.21M | 56.83M | 62.23M | 70.80M | 75.62M |
| Gross Profit | -54.14M | -56.65M | -62.05M | -70.52M | -75.41M |
| SG&A Expenses | 32.68M | 33.07M | 33.80M | 35.45M | 36.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.89M | 89.90M | 96.03M | 106.25M | 112.62M |
| Operating Income | -86.82M | -89.72M | -95.85M | -105.96M | -112.40M |
| Income Before Tax | -84.95M | -108.09M | -87.76M | -96.48M | -107.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -84.95 | -108.09 | -87.76 | -96.48 | -107.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.95M | -108.09M | -87.76M | -96.48M | -107.25M |
| EBIT | -86.82M | -89.72M | -95.85M | -105.96M | -112.40M |
| EBITDA | -85.40M | -88.22M | -94.29M | -104.27M | -110.65M |
| EPS Basic | -1.93 | -2.63 | -2.66 | -3.24 | -4.03 |
| Normalized Basic EPS | -1.21 | -1.64 | -1.67 | -2.03 | -2.53 |
| EPS Diluted | -1.93 | -2.63 | -2.66 | -3.24 | -4.03 |
| Normalized Diluted EPS | -1.21 | -1.64 | -1.67 | -2.03 | -2.53 |
| Average Basic Shares Outstanding | 191.64M | 159.61M | 135.58M | 123.94M | 108.62M |
| Average Diluted Shares Outstanding | 191.64M | 159.61M | 135.58M | 123.94M | 108.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |